We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

46 hedge funds and large institutions have $1.21M invested in Oncolytics Biotech in 2024 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 7

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

10% more capital invested

Capital invested by funds: $1.1M → $1.21M (+$107K)

10% more funds holding

Funds holding: 42 → 46 (+4)

0.15% more ownership

Funds ownership: 1.55% → 1.71% (+0.15%)

Holders
46
Holders Change
+4
Holders Change %
+9.52%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
14
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$102K
2
National Bank of Canada
National Bank of Canada
Quebec, Canada
+$44.7K
3
IAIM
International Assets Investment Management
Florida
+$27.1K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$26K
5
Goldman Sachs
Goldman Sachs
New York
+$17.1K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$69K
2
LFCM
Long Focus Capital Management
Puerto Rico
-$34.8K
3
TSS
Two Sigma Securities
New York
-$12.3K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$11.3K
5
Osaic Holdings
Osaic Holdings
Arizona
-$6.71K
Name Holding Trade Value Shares
Change 		Change in
Stake
KWM
26
Kingsview Wealth Management
Oregon
$11K +$1.04K +1,000 +9%
PI
27
PFG Investments
New York
$9.98K +$442 +425 +4%
PAS
28
Professional Advisory Services
Florida
$9K – – –
AF
29
Allworth Financial
California
$7.44K +$6.71K +6,452 +323%
BNP Paribas Financial Markets
30
BNP Paribas Financial Markets
France
$7.13K -$6.15K -5,911 -43%
CMA
31
Cedar Mountain Advisors
Oregon
$5.16K – – –
AWM
32
Activest Wealth Management
Florida
$4.57K – – –
Wells Fargo
33
Wells Fargo
California
$4.02K – – –
BCWM
34
Ball & Co Wealth Management
Tennessee
$4K +$4.57K +4,393 New
BlackRock
35
BlackRock
New York
$2.74K +$3.12K +3,000 New
IA
36
IFP Advisors
Florida
$2.29K +$4 +4 +0.2%
Osaic Holdings
37
Osaic Holdings
Arizona
$1.88K -$6.71K -6,452 -76%
Carson Wealth (CWM LLC)
38
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
SPIA
39
Steward Partners Investment Advisory
New York
$914 +$1.04K +1,000 New
BHWM
40
Beaird Harris Wealth Management
Texas
$754 +$858 +825 New
TWC
41
TD Waterhouse Canada
Ontario, Canada
$507 – – –
MCM
42
MAI Capital Management
Ohio
$481 +$547 +526 New
JFA
43
JNBA Financial Advisors
Minnesota
$192 – – –
DWM
44
Dogwood Wealth Management
Kansas
$133 +$152 +146 New
AF
45
Aviso Financial
Ontario, Canada
$48 – – –
WWM
46
Wolff Wiese Magana
California
$29 – – –
Citadel Advisors
47
Citadel Advisors
Florida
– -$69K -79,249 Closed
LFCM
48
Long Focus Capital Management
Puerto Rico
– -$34.8K -40,000 Closed
TSS
49
Two Sigma Securities
New York
– -$12.3K -14,079 Closed
PS
50
Principal Securities
Iowa
– -$2.61K -3,000 Closed
1
2
3

ONCY Hedge Fund Activity: Q4 2024 in Review

46 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2024, worth a combined $1.21M — up 9.7% from $1.1M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ONCY positions and 6 closed out — a net gain of 4 holders — while 14 added to existing stakes and 7 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $102K. The largest seller was Citadel Advisors, exiting entirely with an estimated $69K sold.

  • 46 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2024, up from 42 in Q3 2024.
  • Funds reported $1.21M of Oncolytics Biotech stock for Q4 2024, up 9.7% quarter-over-quarter.
  • 10 funds opened new Oncolytics Biotech positions in Q4 2024 and 6 closed out, a net change of +4 holders.
  • The largest Oncolytics Biotech buyer in Q4 2024 was Virtu Financial, an estimated $102K added.
  • The largest Oncolytics Biotech seller in Q4 2024 was Citadel Advisors, an estimated $69K sold.

Based on aggregated 13F filings for Q4 2024.